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ABSTRACT
Most cancers rely on aerobic glycolysis to generate energy and metabolic 
intermediates. To maintain a high glycolytic rate, cells must efficiently export lactic 
acid through the proton-coupled monocarboxylate transporters (MCT1/4). These 
transporters require a chaperone, CD147/BASIGIN (BSG) for trafficking to the plasma 
membrane and function.
To validate the key role of these transporters in lung cancer, we first analysed 
the expression of MCT1/4 and BSG in 50 non-small lung cancer (NSCLC) cases. These 
proteins were specifically upregulated in tumour tissues. We then disrupted BSG in 
three NSCLC cell lines (A549, H1975 and H292) via ‘Zinc-Finger Nucleases’. The three 
homozygous BSG-/- cell lines displayed a low MCT activity (10- to 5-fold reduction, for 
MCT1 and MCT4, respectively) compared to wild-type cells. Consequently, the rate of 
glycolysis, compared to the wild-type counterpart, was reduced by 2.0- to 3.5-fold, 
whereas the rate of respiration was stimulated in BSG-/- cell lines. Both wild-type and 
BSG-null cells were extremely sensitive to the mitochondria inhibitor metformin/
phenformin in normoxia. However, only BSG-null cells, independently of their LKB1 
status, remained sensitive to biguanides in hypoxia in vitro and tumour growth in 
nude mice. Our results demonstrate that inhibiting glycolysis by targeting lactic acid 
export sensitizes NSCLC to phenformin. 
INTRODUCTION 
Non-small cell lung cancer (NSCLC) is one of the 
most common causes of death from cancer worldwide, 
accounting in 2009 for 30% and 26% of all male and 
female cancer deaths, respectively [34]. The overall 5-year 
survival rate of patients with metastatic disease remains 
less than 15% [7]. Thus, a better understanding of the 
molecular mechanisms driving lung tumourigenesis is 
crucial and will provide enormous benefit in developing 
new pharmacological treatments. 
Tumour cells are characterized by excessive aerobic 
glycolysis that is a hallmark of cancer cells [1, 31]. 
The high consumption of glucose and consequent high 
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production of lactate is a constant feature of most cancers, 
therefore high expression of glucose transporters and 
glycolytic enzymes is widely observed [2, 3, 8, 14, 24]. 
In addition, it is necessary to extrude the lactate produced 
to avoid lactic acidosis, which may act as a negative 
feedback mechanism to inhibit glycolysis [24, 35]. 
Monocarboxylate transporters (MCTs) constitute a family 
of 14 proton-linked plasma membrane transporters. Only 
MCT1 and MCT4 have been consistently shown to be 
upregulated in several human cancers [25] and to play an 
important role in maintaining glycolysis. For localization 
in the plasma membrane and for activity, these isoforms 
require a chaperone named CD147/BASIGIN (BSG) [15, 
30, 38]
BSG, also known as EMMPRIN (Extracellular 
Matrix Metalloproteinase Inducer), is an evolutionary 
conserved protein that belongs to the immunoglobulin 
(Ig) superfamily. It is a widely distributed heavily 
glycosylated type I transmembrane glycoprotein [14, 15] 
and is expressed at high levels mainly in metabolically 
active cells such as lymphoblasts and malignant tumour 
cells [9, 37, 40]. BSG has been proposed to effect 
metalloproteinases (MMP) that degrade the extracellular 
matrix [37], tumour growth, chemoresistance [12, 13, 41, 
42] and metastasis [22, 37]. However, the role of MCTs/
BSG in lung cancer is controversial and poorly elucidated 
[16, 20, 27]. Therefore, we aimed to understand the role of 
MCTs/BSG in lactic acid extrusion, pH homeostasis and 
lung tumour growth. In this study we first observed that 
MCT1, MCT4 and BSG were overexpressed in human 
lung cancers when compared to adjacent non-tumour 
tissue. Therefore, we chose three NSCLC cell lines 
(A549, H1975 and H292) one of which was defective 
in LKB1 (A549) to analyse the impact of targeting the 
MCT activity on energy metabolism, on in vitro cell 
proliferation, and on in vivo tumour growth. We exploited 
RNA interference knockdown or Zinc Finger Nucleases 
knockout of a single gene, BSG, to reduce the activity of 
both MCT1 and MCT4. We report that the disruption of 
BSG decreased the expression and activity of MCT1 and 
MCT4, decreased the rate of glycolysis, increased the 
rate of respiration and sensitized the three BSG-/- tumour 
cell lines to the inhibition of OXPHOS by metformin/
phenformin (mitochondrial complex I inhibitors) in vitro 
and in vivo.
RESULTS
MCT expression in lung tumours
First, we analysed the expression of MCTs and BSG 
in a series of human lung cancer tissues. We studied 50 
cases of non-small cell lung cancer (NSCLC). The series 
comprised squamous cell carcinoma tumours (n=8), 
adenocarcinomas (n=29) and other types (n=13). All the 
cases had available adjacent non-tumour tissue that was 
also studied. We observed that MCT1, MCT4 and BSG 
were significantly overexpressed in tumour samples when 
compared to adjacent non-tumour tissue (Fig. 1, Table 1). 
According to the IARC, the most common histological 
types are squamous cell carcinomas and adenocarcinomas 
[36]. The levels of the three components of the lactate 
transport complex differed between the two histological 
types. MCT1 and MCT4 were expressed in all squamous 
cell carcinoma type cases, and BSG was expressed in 60% 
of the cases. MCT1, MCT4 and BSG were expressed in 
20%, 30% and 40% of the cases of adenocarcinomas, 
respectively (Table 1). 
Downregulation of BSG and MCT4 sensitizes 
A549 cells to oligomycin in normoxia
After confirming the expression of these biomarkers 
in lung tumours and taking into account the overlapping 
activity of both MCT1 and MCT4, we decided to 
evaluate the effect on growth of MCT4 and BSG 
silencing in A549 cells or of MCT1 pharmacological 
inhibition (AstraZeneca, iMCT1/2; AR-C155858). The 
silencing of MCT4, by shRNA, decreased MCT4 and 
BSG expression in hypoxia (Fig. 2A). Moreover, as 
expected, BSG silencing induced a parallel decrease in 
the expression of MCT1 and MCT4 in both normoxia 
and hypoxia (Fig. 2A). Silencing of MCT4 or BSG had 
only very modest effect on clonal growth in normoxia 
and hypoxia even in the presence of iMCT1/2 (Fig. 2B). 
Blockade of OXPHOS by oligomycin did not impact on 
the growth rate when the cells were cultured in hypoxia 
(1% O2) (Fig. 2B, right panel). By contrast, cell growth 
was severely affected in normoxia by oligomycin, which 
was magnified in the presence of iMCT1/2 (Fig. 2B). 
This experiment demonstrated that hypoxic cells, in spite 
of appreciable silencing of MCT4 and MCT1 inhibition, 
remained resilient to growth inhibition by targeting 
glycolysis. Indeed, shRNA targeting of MCT4 did not 
totally abolish the activity of this transporter, and the 
residual expression might explain this hypoxic resistance 
to MCT1 and OXPHOS blockade. In the absence of a 
specific pharmacological inhibitor of MCT4, and taking 
into account the interdependency between MCTs and 
their chaperone, we decided to develop BSG-null cells to 
further explore the role of MCTs in targeting glycolysis 
and tumour growth. 
Generation of BSG -/- lung cancer cell lines using 
Zinc Finger Nucleases
First, we disrupted the BASIGIN (BSG) gene in three 
different non-small lung cancer cell lines (A549, H1975 
and H292) by using Zinc Finger Nucleases. Knocked-out 
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Figure 1: Immunohistochemical expression of the monocarboxylate transporters, MCT1 and MCT4, and their 
chaperone protein BSG in lung cancer samples. All markers were upregulated at the plasma membrane of tumour cells. Pictures 
were obtained using the microscope Olympus BX61, at 40 magnification.
Oncotarget4www.impactjournals.com/oncotarget
candidates lacking expression of BSG (Fig. 3A, Fig. 4A) 
were identified and selected for further characterization. 
The site that was cut was amplified by PCR and the 
sequence and mutational independent status of the clones 
was confirmed by sequencing. Next, we analysed the 
expression of the MCT1 and MCT4 isoforms in normoxia 
and hypoxia 1% O2 in these cells Immunoblotting showed 
that the MCT1 protein was not detectable in BSG-/- A549 
cells compared to wild-type (wt) cells, while MCT4 
expression was highly reduced. We also observed that the 
non-detectable MCT4 expression in normoxia in BSG-
/- cells remained inducible in hypoxia (Fig. 3A). Similar 
results were obtained for the H1975 (Fig. 4A) and H292 
cell lines (data not shown). Knockout (KO) of the BSG 
gene in these cells induced a huge decrease in the protein 
level of MCT1 and MCT4 in both normoxia and hypoxia.
Moreover, we demonstrated by qPCR a low level 
of transcript expression of BSG, but no evidence of 
changes in mRNA expression of MCT1, while MCT4 
expression increased by 2-fold in both A549 BSG-/- clones 
(Fig. 3B). This stability or even increase in MCT4 mRNA 
contrasted with the virtual loss of the corresponding gene 
product. We further assessed the impact of BSG disruption 
on the in vitro growth rates of the A549- (Fig. 3C, 3D) 
and H1975-derived cell lines (Fig. 4B) in normoxia. All 
BSG-null cells, excepting the BSG-/- A549 clone (C153), 
displayed a normal growth rate compare to the parental 
cells (reduction of less than 5% for BSG-/- cells). 
Figure 2: Downregulation of MCT4 and BSG. A: Immunoblot analysis of MCT1, MCT4 and BSG in cells transfected with either 
scrambled shRNA or shRNA targeting MCT4 and BSG and culture in normoxia (21% O2) and hypoxia (1% O2). ARD1 used as a loading 
control; B: Clonal growth in the absence or presence of oligomycin (1μg/mL) or iMCT1/2 AR-C155858 (300nM) or both compounds either 
in normoxia and hypoxia for 8 days.
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Figure 3: Effect of BSG disruption in lung carcinoma cell line A549. A: Immunoblot analysis of MCT1, MCT4 and BSG in wt 
and BSG-/- A549 cell lines maintained in normoxia (N) or hypoxia (1% O2) (H) for 48h. ARD1 was used as a loading control; B: mRNA 
levels of MCT1, MCT4 and BSG in wt and BSG-/- cells (Clones C153 and C113) in hypoxia 1% O2 C: Total biomass of wt and BSG
-/- A549 
(Clones C153 and C113) cells was evaluated over time using the sulphorhodamine B assay; D: Clonal growth of wt and BSG-/- cells (Clones 
C153 and C113) in normoxia (21% O2) and hypoxia (1% O2); E: [
14C]-Lactic acid uptake of wt and BSG-/- A549 cells in the absence or 
presence of iMCT1/2 (300nM) in hypoxia (1% O2); F: Time-course of intracellular lactate concentration in response to glucose (25mM) 
added in the presence of either DMSO or iMCT1/2 (300nM). (*** p <0.0001).
Oncotarget6www.impactjournals.com/oncotarget
BSG gene disruption inhibits the MCT activity 
and increases the intracellular lactate pool
We quantified the membrane activity of both MCT1 
and MCT4 by a direct measure of the initial rates of 
lactic acid transport in hypoxic A549 parental and BSG-
/- cells. The uptake of 14C-lactic acid was measured at a 
low external pH (6.0) to favour its entry in the absence 
or presence of the specific iMCT1/2 (Fig. 3E). Thus, we 
demonstrated that the ability of MCT1 to transport lactate 
was severely suppressed (>90%) in BSG-/- cells, while 
that of the hypoxia-induced MCT4 is only decreased by 
60% compared to parental cells. The transport activity of 
MCT1/4 was also evaluated by measuring the intracellular 
lactic acid pools (Fig. 3F). After 1h of glucose starvation, 
A549-derived cells rapidly accumulated intracellular lactic 
acid on addition of glucose to reach an equilibrium state 
within 3h. In accordance with the above experiments on 
the MCT transport activity, BSG-/- A549 cells accumulated 
a much higher level of intracellular lactic acid than 
parental cells. From 2-3mM lactate in parental cells to 
11-12mM in BSG-/- cells (Fig. 3F). Treatment of the cells 
with iMCT1/2 further increased the intracellular lactate 
pool of the BSG-null cells (20mM) whereas parental cells 
remained less sensitive. 
In the highly glycolytic H1975 cell line, our results 
showed that the BSG disrupted cells accumulated higher 
levels of intracellular lactic acid (33mM), than the wild-
type cells (3mM) (Fig. 4C) and the BSG-/- A549 cells (Fig. 
3F). However, these cells remained less sensitive to MCT1 
inhibition due to the high decrease in MCT1 expression of 
BSG KO (Fig. 4A). 
Taken together, these findings demonstrate that BSG 
plays a central role in controlling lactic acid export and 
therefore the rate of glycolysis of non-small lung cancer 
cells. 
Figure 4: Effect of BSG disruption in lung carcinoma cell line H1975. A: Immunoblot analysis for MCT1, MCT4 and BSG in 
wt and BSG-/- H1975 cell lines maintained in normoxia or hypoxia (1% O2) for 48h. ARD1 was used as a loading control; B: Total biomass 
of wt and BSG-/- H1975 cells was evaluated over time using the sulphorhodamine B assay; C: Time-course of the intracellular lactate 
concentration in response to glucose (25mM) added in the presence of either DMSO or iMCT1/2 (300nM). 
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Disruption of BSG decreases the rate of glycolysis 
and increases OXPHOS in different lung cancer 
cell lines
To further investigate the interplay between 
glycolysis and OXPHOS, under the conditions where 
lactic acid export was pharmacologically or genetically 
reduced, we used the Seahorse XF24 Analyser to measure 
the extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) of our wt and BSG-/- cell lines. 
In the presence of glutamine (2mM) and glucose (10mM), 
BSG-null A549 cells showed a 2-fold reduction in 
ECAR compared to wt cells (Fig. 5A), whereas the more 
glycolytic cell line H1975 (ECAR=40 in H1975 and 10 in 
A549) showed a 3.4-fold reduction in ECAR upon BSG 
KO compared to parental cells (Fig. 5B). EACR values 
were further reduced (1.8-fold) in A549- and H1975-
derived cell lines in the presence of iMCT1/2, reflecting 
inhibition of glycolysis by limiting lactic acid export (Fig. 
5A, 5B). Addition of oligomycin or phenformin stimulated 
by 3- to 4-fold ECAR, respectively in wt and BSG-/- A549 
cells. However, the ECAR of wt and BSG-/- H1975 cells 
was only increased by 1.3- to 1.4-fold, respectively (Fig. 
5A, 5B). These results indicate that, in contrast to the 
H1975 cell line, A549 cells were moderately glycolytic 
as they only used one third of their glycolytic potential. 
By contrast, the OCR values were high in both A549 
and H1975 cell lines. These values were even increased in 
BSG-null cells compared to wt cells and further increased 
in response to MCT1 inhibition (Fig. 5C, 5D). Respiration 
was dramatically reduced in response to the mitochondrial 
complex I inhibitor phenformin (Fig. 5C, 5D). 
Figure 5: Analysis of bioenergetic pathways in lung carcinoma cells disrupted for BSG. A, B: Real time analysis of the 
extracellular acidification rate (ECAR) of wt and BSG-/- A549 (A) or H1975 (B) cells using a Seahorse XF24 analyzer after injection of 
glucose (10mM), iMCT1/2 (1μM), oligomycin (1μg/mL) or phenformin (50μM) ; C, D: Real time analysis of the oxygen consumption rate 
(OCR) of wt and BSG-/- cells A549 (C) or H1975 (D) using a Seahorse XF24 analyzer after injection of the compounds described above. 
Data represent the average of at least three independent experiments. 
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MCT inhibition sensitizes lung cancer cells to 
phenformin in hypoxia
Deletion of BSG did not affect in vitro clonal growth 
of either A549 or H1975 cells, even in the presence of 
iMCT1/2 (Fig. 6A, 6B). However, only wt A549 cells 
displayed an extremely high sensitivity to metformin/
phenformin or oligomycin (not shown), while the more 
glycolytic H1975 cells remain insensitive (Fig. 6B). This 
is in agreement with the high oxidative/low glycolytic 
activity of A549 cells and perhaps also with the loss of 
LKB1 (see discussion) (Fig. 6A). However, in hypoxia, 
parental A549 cells lost sensitivity to OXPHOS inhibitors, 
which is consistent with optimal induction of glycolytic 
enzymes through stabilization of the hypoxia-inducible 
factor (HIF). In sharp contrast to wt cells, BSG-null cells 
A549 and H1975 retained a high level of sensitivity to 
phenformin/metformin alone or in combination with 
iMCT1/2 (Fig. 6A, 6B). This striking difference between 
wt and BSG-null cells in hypoxia could easily be explained 
by the failure of BSG-/- cells to express sufficient hypoxia-
inducible MCT4 to sustain glycolysis (Fig. 3A, Fig. 4A). 
These results were confirmed in another glycolytic 
non-small lung carcinoma cell line, H292, disrupted for 
the BSG gene (data not shown), highlighting the fact that 
targeting lactic acid export sensitizes lung carcinoma cell 
lines to biguanides and thus suppresses their growth in 
both normoxia and hypoxia. 
Figure 6: Disruption of BSG sensitizes lung carcinoma cells to phenformin in both normoxia and hypoxia. A: Clonal 
growth of wt and BSG-/- A549 cells in the presence or absence of iMCT1/2 (300nM), metformin (Metf.-1mM), phenformin (Phenf. -50μM) 
or in combination. Cells were maintained in normoxia for 10 days (upper panel) and in hypoxia (1% O2) for 15 days (lower panel); B: 
Clonal growth of wt and BSG-/- H1975cells in the presence or absence of iMCT1/2 (300nM), Phenformin (Phenf. -50μM) or in combination 
iMCT1/2. Cells were maintained in normoxia for 10 days (upper panel) and in hypoxia (1% O2) for 12 days (lower panel).
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Combination of inhibition of glycolysis and 
OXPHOS decreases tumour growth in vivo
To assess the effect of BSG disruption in vivo, we 
compared the tumourigenicity of wt and BSG-/- A549 cells. 
Nude mice were s.c. injected with both cell populations. 
Surprisingly, BSG-/- cells generated bigger tumours than 
wt cells (Fig. 7 A,B-black lines). However, phenformin 
greatly reduced the tumour burden in BSG-/- cells than in 
wt cells (Fig. 7A and B). To confirm the expression levels 
of BSG and MCTs, tumours were collected at the end of 
the experiment and tested by immunohistochemistry. As 
expected, BSG and MCT1 expression was not detected in 
BSG-/- tumors while MCT4 was present, although with a 
weaker expression. Moreover, treatment with phenformin 
did not alter the expression of BSG, MCT1 or MCT4. 
(Fig. 7C).
Figure 7: Xenograft tumour growth. Wt (A) and BSG-/- cells (B) A549 cells were s.c. injected into the back of athymic nude mice. 
5% sucrose with and without phenformin (200 mg/kg) was added to the drinking water for all the mice. Ten mice were studied per condition 
(*p<0.05, **p<0,001, ***p<0,0001); C: Immunohistochemical expression of MCT1, MCT4 and BSG in A549 wt and A549 BSG-/- tumor 
samples. Pictures were obtained using the microscope Olympus.
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DISCUSSION
Upregulation of glycolysis and adaptation to 
acidosis are key events in the transition from in situ to 
invasive cancer [11].MCTs may play an important role 
through their involvement in exporting lactic acid [10]. 
MCTs have been described to be upregulated in several 
cancers [25]. However, expression in lung cancer is 
still controversial [16, 20, 27]. In the present study, 
we showed that MCTs are upregulated in lung tumour 
tissue when compared to adjacent non-tumour tissue. 
Moreover, we detected MCT1 and MCT4 in the plasma 
membrane of all the histological types studied. These 
results were in accordance with those of Koukourakis 
and co-workers [16]. However, they did not describe the 
cellular localization and histological type of the samples 
stained for MCT. Interestingly, we found that MCT1 
and MCT4 were overexpressed in the squamous cell 
carcinoma subtype and MCT4 was overexpressed in all 
cases of adenocarcinoma subtypes, suggesting a different 
expression pattern of the histological types. However, 
due to the small number of cases, this study should be 
extended and replicated to obtain more solid statistically 
relevant data.
To understand the biological role of MCTs, we 
developed a strategy to inhibit their activity in a lung 
carcinoma cell line. For MCT1, we used the specific 
MCT1/2 inhibitor (AR-C155858; AstraZeneca) and found 
that it did not affect in vitro cell growth in either normoxia 
or hypoxia. In normoxia, A549 cells relied mainly on 
OXPHOS rather than on glycolysis [39], thus inhibiting 
MCT1, even with low expression of MCT4, did not 
affect cell clonogenicity. In hypoxia, in which OXPHOS 
was reduced and glycolysis enhanced, cells were able 
to survive and proliferate due to the presence of HIF-1-
induced MCT4. Although, regulation of MCT expression 
is still not fully understood, one of the best characterized 
mechanisms of MCT regulation occurs through co-
expression with BSG. As no pharmacological inhibitor of 
MCT4 is yet available and as previous published results 
[17] showed that the major pro-tumour action of BSG is 
mediated through bioenergetics, namely by controlling 
lactate transport, we decided to knockdown both MCT4 
and BSG. As shRNA targeting of MCT4 and BSG failed 
to completely stop the growth of A549 cells in hypoxia, 
we decided to disrupt the BSG gene. We observed that 
KO of BSG resulted in a decrease in MCT1 and MCT4 
expression. We observed that the mRNA level remained 
unchanged for MCT1 but increased 2-fold for MCT4 
in the absence of BSG. As we previously reported for 
the LS174 colon cell line [17], BSG KO did not affect 
expression of MCTs at the transcriptional/translational 
levels but severely reduced the trafficking of MCTs from 
the endoplasmic reticulum (ER) to the plasma membrane 
[15]. In the absence of the chaperone (BSG), MCT1 and 
MCT4 were very unstable in the ER, which explained their 
decreased expression as detected by immunoblotting (Fig. 
3A) and reduced activity in lactic acid transport (Fig. 3E). 
Nevertheless, BSG gene disruption did not totally suppress 
the activity of MCT4 in these cells.
These results support the idea that MCTs may use 
an alternative chaperone for processing to the plasma 
membrane, as already suggested previously by our group 
[25, 27], or that MCTs alone could reach the plasma 
membrane but with a very low efficiency. 
Targeting a metabolic pathway can be tricky 
due to the high plasticity of the metabolic networks of 
cancer cells. Thus, we decided to analyze the impact of 
disrupting BSG and OXPHOS on in vitro growth and 
tumourigenicity. 
The anti-diabetic biguanide drugs metformin 
and phenformin used in the clinic have been shown to 
inhibit mitochondria complex I [6, 23], with no toxicity 
for metformin and little toxicity for phenformin. More 
recently, these biguanides have shown interesting new 
potential applications in oncology [5, 18, 19, 29, 32]. In 
this context, we report here that the three NSCLC parental 
cell lines (A549, H292, H1975) or their BSG-/- derivatives 
were highly sensitive to metformin or phenformin for in 
vitro growth in normoxia as the cells derived their energy 
mainly from respiration (Fig. 6A,B and data not shown). 
These findings are in good agreement with the report of 
Wu and co-workers stating that A549 cells rely more on 
OXPHOS than on glycolysis [39]. However, phenformin, 
which induced substantially glycolysis (ECAR, Fig. 5A,B), 
did not rescue in vitro growth in normoxia (Fig. 6A). We 
believe that the low expression of MCT1 and MCT4, 
even in parental cells, precluded efficient glycolysis and 
therefore proliferation in normoxia. Another explanation 
could be related to the toxicity generated by an increase 
in reactive oxygen species (ROS) production as recently 
proposed by Shackelford and co-workers [32]. However, 
in hypoxia the three parental cell lines became insensitive 
to metformin/phenformin alone or in the presence of 
MCT1 inhibitor because MCT4 was highly expressed, 
thereby restoring glycolysis. By contrast, the BSG-null 
cells, and particularly in the presence of iMCT1, showed a 
high level of sensitivity to phenformin, which is consistent 
with ATP crisis or “metabolic catastrophe”, as discussed 
recently [8] and reported for colon adenocarcinoma and 
glioblastoma cells [19](Fig. 6A,B). 
Only the BSG-null tumours were sensitive to 
phenformin (Fig. 7). The fact that parental cells were 
totally insensitive to phenformin, which contrasted 
with the in vitro data, may suggest that the tumour cells 
were exposed to a hypoxic microenvironment favouring 
glycolysis and /or production of a low level of ROS. 
Another explanation for the attenuated sensitivity to 
phenformin in vivo in both parental and BSG-null cells is 
that the concentration of phenformin delivered in vivo was 
lower than the concentration of 50μM used in vitro. 
Moreover, Shackelford and co-workers showed 
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that inactivation of the suppressor gene LKB1 dictated a 
therapeutic response of NSCLC to phenformin [6, 32]. In 
this context, they showed that cells with mutated LKB1 
(as in A549 cells) were more sensitive to phenformin 
and that this effect was dependent on AMPK activation. 
They hypothesized that without phosphorylation of 
AMPK through LKB1, these cells lacked the mitophagy 
induced by the protein ULK1, a downstream target of 
AMPK. Thus cells accumulated defective mitochondria 
and did not neutralize ROS that induced apoptosis. 
This is an interesting explanation, however our studies 
contradict this explanation since we found a high 
sensitivity to phenformin independently of the LKB1 
status. We propose instead that the level of sensitivity to 
phenformin is dictated by the glycolytic rate. In normoxia, 
the cell line with the lowest glycolytic rate (A549) was 
the most sensitive. A decrease in glycolysis by BSG 
disruption rendered the three cell lines equally sensitive to 
phenformin in normoxia and hypoxia. 
In vitro studies of cells cultured in monolayers have 
given information about cell-autonomous metabolism, 
however they do not reflect the real physiological 
microenvironment in tumours. In vivo studies showed that 
BSG disruption did not reduce tumour growth as shown 
by other groups [4, 33]. In fact, tumour growth increased 
approximately 4-fold for BSG-/- cells compared to wt 
cells. These results could reflect a clonal growth effect. 
However, in vitro studies showed that these KO cells had 
the same proliferation rate as wt cells. In addition we 
observed that phenformin drastically inhibited tumour 
growth, with a stronger impact on BSG-/- cells compared 
to wt cells. 
CONCLUSION
The results obtained by inhibiting the MCTs/
BSG complex are promising. Nevertheless, we do not 
yet assume that MCTs are effective targets for cancer 
therapy. More effort is needed to prove that inhibition of 
metabolism, more specifically lactate transport, may be an 
alternative therapeutic strategy to use in the treatment of 
certain types of cancer. Therefore, the present work is an 
attempt to provide new data supporting the exploitation of 
MCTs/BSG as targets in lung cancer therapy.
MATERIAL AND METHODS
Tissue samples
Representative formalin-fixed paraffin-embedded 
samples from primary lung tumour tissues were retrieved 
from the archives of the Department of Pathology of 
Hospital S. João, Porto, Portugal. The tumours were 
classified according to the WHO criteria [36]. This 
cohort included 50 cases of non-small cell lung cancer 
(NSCLC), 8 were squamous cell carcinomas (SCC), 29 
adenocarcinomas (AC) and 13 from other types. Adjacent 
non-tumour tissue from each case was also selected. 
Cells and culture conditions
The lung adenocarcinoma cell lines A549 (obtained 
from American Type Culture Collection, Manassas, 
VA, USA) and H1975 (kindly provided by Dr. Patrick 
Brest, Fr) were maintained in Dulbecco’s modified eagle 
medium (DMEM, Gibco, Life Technologies Corporation) 
supplemented with 10% foetal calf serum (FCS – Gibco 
Life Technologies Corporation), penicillin (10units/mL) 
and streptomycin (10μg/mL), in a humidified atmosphere 
of 5% CO2 at 37 °C. Incubation in hypoxia was carried out 
at 1% oxygen.
Immunohistochemistry
Sections of 3-μm were used for 
immunohistochemical (IHC) analysis. IHC for MCT1 
and CD147/BASIGIN was performed according to the 
avidin-biotin-peroxidase methodology (R.T.U. Vectastin 
Elite ABC kit; Vector Laboratories Inc.), as previously 
described by our group [26]. MCT4 IHC was performed 
with the Ultravision Detection System Anti-polyvalent, 
HRP (Lab Vision Corporation, Thermo Fisher Scientific), 
as previously described [21, 28]. In brief, paraffin 
embedded sections were deparaffinized in xylene and 
hydrated in a graded series of ethanol solutions. For 
antigen retrieval, slides were incubated either with 1mM 
EDTA buffered solution, pH 8.0 (CD147) or citrate 
buffer, pH=6.0 (MCT1, MCT4) for 20 min in a water 
bath at 98°C. After endogenous peroxidase inactivation, 
incubation with the primary antibody was performed 
overnight for MCT1 and CD147 and for 2 h for MCT4 at 
room temperature. Tissues were stained with 3,3’-diamino-
benzidine (DAB+ Substrate System, DakoCytomation, 
Dako, Agilent Technologies Company) and counterstained 
with haematoxylin. Colon carcinoma tissue was used as a 
positive control for MCT1, MCT4 and CD147. Stained 
slides were evaluated and then photographed under a 
bright field microscope. Sections were scored for plasma 
membrane expression following a semi-quantitative 
criterion. The score used was the sum of the percentage of 
positive cells (0, negative; 1, less than 5% positive cells; 2, 
25% to 50% positive cells; and 3, more than 50% positive 
cells) and the staining intensity (0, negative; 1, weak; 2, 
moderate; 3, strong). Scores between 0 to 3 were classified 
as negative and 4 to 6 as positive [26]. 
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Generation of BSG-null cells using Zinc Finger 
Nucleases (ZFNs)
To generate A549, H1975 and H292 KO cells for 
BASIGIN, two ZFN plasmids (designed by Sigma-Aldrich 
CKOZFN1227-1KT, CompoZr Custom ZFN) targeting 
BASIGIN exon 2 were transfected using JetPRIME® 
Transfection Reagent (Polyplus-transfection SA), 
according to the manufacturer’s instructions. Transfected 
cells were detected by fluorescence-activated cell sorting 
(FACS), with a CD147 (MAB972, R&D Systems) primary 
antibody and with a PE-conjugated anti-mouse IgG (115-
115-164, Jackson ImmunoResearch) secondary antibody. 
Negative cells for BSG were selected, sorted and cloned 
by dilution in 96 wells. The absence of BSG expression 
was confirmed by immunoblotting and only clones lacking 
the two alleles of BSG were analysed.
 [14C]-Lactate Uptake
 [14C]-lactate uptake was measured to determine 
lactate transport in A549 cells, as previously published 
[17]. The protein concentration was determined to 
normalize the radioactivity to the protein content of the 
cells in each dish. [14C]-L-lactate uptake was expressed as 
counts per million per mg of protein.
Intracellular Lactate Assay 
A549 and H1975 cells (3x105) were seeded in 
12-well plates and allowed to adhere overnight. After 
incubation in hypoxia (1% O2) for 24h, cells were washed 
twice and maintained in DMEM without glucose, pyruvate 
and serum for 1h with either DMSO or iMCT1/2 (300nM). 
DMEM 5% FCS with either DMSO or iMCT1/2 was 
added and cells were collected at the indicated times (0, 
1, 3 and 6h). For determination of the intracellular lactate 
concentration, cells were washed once with cold PBS1x 
and cold water and lysed with 200μL cold water. 50μL 
of cell lysate was assayed in 96-well plates in triplicate 
to measure the lactate concentration using a lactate 
colorimetric assay kit (K607-100, Biovision Incorporated).
Immunoblotting
Cells were lysed in 1.5x SDS sample buffer and 
incubated for 15min at 95°C. Protein concentrations were 
determined using the BCA Assay. 40μg of protein was 
separated on 8% SDS polyacrylamide gels and transferred 
onto polyvinylidene difluoride membranes (Millipore). 
Blots were blocked in 5% non-fat milk in TN buffer 
(50 mM Tris-HCl pH7.4, 150 mM NaCl) and incubated 
overnight with the primary antibodies for CD147/BSG 
(1:500; MAB972, R&D Systems), MCT4 (1:1000; SC-
50329, Santa Cruz Biotechnology) and for MCT1 (1: 
3000; rabbit polyclonal antibodies against the C-terminal 
last 15 residues, prepared in the laboratory). The 
polyclonal antibody to arrest-defective-1 protein (ARD1) 
was used as loading control (1:30000). Bands were 
detected with the ECL system (Amersham Biosciences) 
after incubation of blots with secondary anti-mouse or 
anti-rabbit antibodies (Promega) coupled to horseradish 
peroxidase.
Clonogenicity assay
A549 and H1975 wt and BSG-/- cells (2x103) were 
seeded in 60-mm dishes and incubated for 24h to adhere. 
Medium was replaced with DMEM 10% FCS with and 
without iMCT1/2 AR-C155858 (300nM) or Phenformin 
(50M) or both for 10 days in normoxia and 15 days in 
hypoxia (1% O2). Dishes were stained with 5% Giemsa 
(Fluka) for 45min to visualize colonies. 
Metabolic Analysis
The extracellular acidification rate (ECAR) and 
the oxygen consumption rate (OCR) were measured 
with a Seahorse XF analyser (Seahorse Bioscience, MA, 
USA). A549 cells (8x104) and H1975 cells (1x105) were 
seeded on seahorse plates and allowed to grow for 24h in 
normoxia. Prior to measurement, Plates were incubated 
for 45min in a non-CO2 incubator at 37°C with seahorse 
medium without glucose, pyruvate, serum or bicarbonate. 
10mM of glucose (Sigma), 300nM of iMCT1/2 
(AstraZeneca, UK), 50μM of phenformin (Sigma) and 
1μM of oligomycin (Sigma) were injected. After each 
addition, three data points of 3min were undertaken to 
determine the oxygen and proton concentrations in the 
medium. The protein concentration was determined to 
normalize OCR and ECAR values. 
Tumour Xenografts
Immunodeficient female nude mice with 
approximately 22g body weight were housed in groups 
of five, under specific pathogen-free, controlled ambient 
conditions. Animal studies were conducted according to 
Centre National de la Recherche Scientifique institutional 
guidelines (Ciepal n° NCE/-165). A549 wt and BSG-/- cells 
(2x106/mouse) suspended in 300μL of serum-free DMEM 
supplemented with insulin-transferrin-selenium (Gibco, 
Life Technologies Corporation) were sub-cutaneously 
injected into the backs of the mice. Water containing 5% 
sucrose with and without 200mg/Kg phenformin (Sigma 
Aldrich) was added to the drinking water, and the daily 
intake fluids were monitored. Sucrose was added to 
make the drinking water palatable (MVCL Appleyard 
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et al. 2012). Fresh phenformin was administered every 
two days. Tumours were measured every 2–3 days using 
a calliper and the volume was determined by using the 
formula: (4π/3) × L/2 × W/2 × H/2, where L represents 
length, W the width, and H the height. Tumours were 
harvested at approximately 1 cm3, fixed and paraffin-
embedded. 
Statistics
For in vitro studies, the GraphPad prism 5 software 
was used, with the Student’s t-test, considering significant 
values to be p<0.05.
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